Argenx, NL0010832176

argenx stock faces Deutsche Bank Hold rating

Published on 11/20/2026 at 10:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Deutsche Bank retained its Hold view on the biotech company. The argenx stock outlook now turns on earnings growth, pipeline progress and commercial execution.

Analyst signal and business context

  • Deutsche Bank retained its Hold rating on argenx while maintaining its valuation view.
  • The latest quarterly figures showed strong profit growth alongside a broader immunology pipeline.
Argenx, NL0010832176, Illustration mit AI erstellt.

On November 19, Markets Insider reported that Deutsche Bank analyst Emmanuel Papadakis retained a Hold rating on argenx and kept the price target at 850 euros. The assessment adds a more cautious sell-side view to the recent discussion around the biotech company's growth outlook.

Deutsche Bank Holds Its View

The report said Papadakis continues to cover argenx within the healthcare sector. The unchanged rating places the emphasis on execution, commercial growth and the company's ability to expand its immunology franchise.

Markets Insider also cited argenx's latest earnings release for the quarter ended June 30. Revenue reached 2.76 billion euros, compared with 947.96 million euros a year earlier, while net profit rose to 821.17 million euros from 245.36 million euros.

Those figures give investors a strong earnings backdrop, while the pipeline remains important for the longer-term valuation. The Hold view suggests that Deutsche Bank is weighing the company's operating progress against the expectations already reflected in the shares.

argenx stock traded at 857.10 euros on Lang & Schwarz at 09:47 CET on Friday, November 20, 2026.

argenx SE at a glance

  • Company: argenx SE
  • ISIN: NL0010832176
  • Ticker: ARGX
  • Lang & Schwarz quote: 857.10 euros at 09:47 CET on November 20, 2026
  • Deutsche Bank rating: Hold
  • Price target: 850 euros

For broader European market context, see the Euro Stoxx 50 market reports.

More news and analyses on argenx stock

Disclaimer...
en | NL0010832176 | ARGENX | boerse | 70539435 | bgmi